ZA200407373B - Sell surface tropomyosin as a target of angiogenesis inhibition. - Google Patents

Sell surface tropomyosin as a target of angiogenesis inhibition. Download PDF

Info

Publication number
ZA200407373B
ZA200407373B ZA200407373A ZA200407373A ZA200407373B ZA 200407373 B ZA200407373 B ZA 200407373B ZA 200407373 A ZA200407373 A ZA 200407373A ZA 200407373 A ZA200407373 A ZA 200407373A ZA 200407373 B ZA200407373 B ZA 200407373B
Authority
ZA
South Africa
Prior art keywords
tpm
antibody
binding
antiangiogenic
peptide
Prior art date
Application number
ZA200407373A
Other languages
English (en)
Inventor
Keith Mccrae
Fernando Donate
Jose Juarez
Andrew P Mazar
Original Assignee
Attenuon Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Attenuon Llc filed Critical Attenuon Llc
Publication of ZA200407373B publication Critical patent/ZA200407373B/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
ZA200407373A 2002-03-15 2004-09-14 Sell surface tropomyosin as a target of angiogenesis inhibition. ZA200407373B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36404702P 2002-03-15 2002-03-15

Publications (1)

Publication Number Publication Date
ZA200407373B true ZA200407373B (en) 2005-09-14

Family

ID=28041863

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200407373A ZA200407373B (en) 2002-03-15 2004-09-14 Sell surface tropomyosin as a target of angiogenesis inhibition.

Country Status (7)

Country Link
US (1) US20050124794A1 (https=)
EP (1) EP1575525A4 (https=)
JP (1) JP2006501139A (https=)
AU (1) AU2003218194A1 (https=)
CA (1) CA2478962A1 (https=)
WO (1) WO2003077872A2 (https=)
ZA (1) ZA200407373B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0301988D0 (sv) * 2003-07-07 2003-07-07 Innoventus Project Ab Active subfragment of an endogenous peptide
WO2006058375A1 (en) * 2004-12-01 2006-06-08 The Royal Alexandra Hospital For Children Identification of compounds for the treatment of proliferative disorders
DE102005002110A1 (de) * 2005-01-17 2006-07-27 Protagen Ag Regulatorische-T-Zellen enthaltend Proteine zur Therapie und Diagnose von Erkrankungen
WO2007075215A2 (en) 2005-10-21 2007-07-05 Attenuon, Llc Identification of novel protein targets on the surface of stressed cells
KR102874711B1 (ko) 2015-12-15 2025-10-23 다케다 파머수티컬 컴패니 리미티드 전장 고분자량 키니노겐(hmwk) 및 절단된 hmwk를 구별하기 위한 펩타이드 정량화 검정법
EP3634442B1 (en) 2017-05-24 2025-04-09 Tets, Viktor, Veniaminovich Method for diagnosis of parkinson's disease
US12535491B2 (en) 2018-04-30 2026-01-27 Viktor Veniaminovich Tets Vaccine comprising protein-targeted (PT) extracellular DNA isolated from bacterial matrix
US11918610B2 (en) 2018-06-29 2024-03-05 Viktor Veniaminovich Tets Methods for diagnosis and treatment of type 1 diabetes
WO2020010214A1 (en) 2018-07-03 2020-01-09 Tets Viktor Veniaminovich Method for assessing and inhibiting aging and means of determining biological age

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6201104B1 (en) * 1998-12-04 2001-03-13 Entremed, Inc. Angiogenesis—inhibiting protein binding peptides and proteins and methods of use
US6342219B1 (en) * 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody compositions for selectively inhibiting VEGF
WO2001034195A1 (en) * 1999-11-12 2001-05-17 Temple University Of The Commonwealth System Of Higher Education Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain 5
US20020077289A1 (en) * 2000-06-02 2002-06-20 Macdonald Nicholas J. Angiostatin and endostatin binding proteins and methods of use

Also Published As

Publication number Publication date
US20050124794A1 (en) 2005-06-09
WO2003077872A3 (en) 2007-05-18
AU2003218194A1 (en) 2003-09-29
CA2478962A1 (en) 2003-09-25
JP2006501139A (ja) 2006-01-12
EP1575525A4 (en) 2008-04-02
EP1575525A2 (en) 2005-09-21
WO2003077872A2 (en) 2003-09-25

Similar Documents

Publication Publication Date Title
Nguyen et al. Pemphigus vulgaris antibody identifies pemphaxin: a novel keratinocyte annexin-like molecule binding acetylcholine
CN107098970B (zh) 结合细胞内prl-1多肽或prl-3多肽的抗体
UA74129C2 (uk) Виділене антитіло або фрагмент антитіла, що є специфічним до онкоембріонального домену ed-b фібронектину (fn) та таким, що безпосередньо з ним зв'язується
JP2009060891A (ja) 特異的な細胞に誘導することができるモジュールと透過性遷移孔複合体（ｐｔｐｃ）のアポトーシス誘発機能を制御するモジュールとを含有するキメラ分子
US8697840B2 (en) Peptide inhibition of lung epithelial apoptosis and pulmonary fibrosis
US20050124794A1 (en) Cell surface tropomyosin as a target of angiogenesis inhibition
CA2906775A1 (en) Bh4 stabilized peptides and uses thereof
US20020077289A1 (en) Angiostatin and endostatin binding proteins and methods of use
US9701733B2 (en) Maspin-based treatment of cancer
US6025142A (en) Hydrophobic u-PAR binding site
ES2242400T3 (es) Proteina que se une a la angiostatina.
US20030082740A1 (en) Histidine proline rich glycoprotein (HPRG) as an anti-angiogenic and anti-tumor agent
EP1305342A2 (en) Human kininogen d5 domain polypeptides and their use
JPH05506981A (ja) ガストリン放出ペプチド受容体
US7119069B2 (en) Human kininogen D3 domain polypeptide as an anti-angiogenic and anti-tumor agent
Nahomi et al. A monoclonal antibody targeted to the functional peptide of αB-crystallin inhibits the chaperone and anti-apoptotic activities
AU2002247129A1 (en) Histidine proline rich glycoprotein (HPRG) as an anti-angiogenic and anti-tumor agent
US10287338B2 (en) Factor VIII protein compositions and methods of treating of hemophilia A
US20080280833A1 (en) Therapeutic Peptides Derived from Urokinase Plasminogen Activator Receptor
JP2005287418A (ja) 細胞殺傷性と細胞死防御性とを併せもつペプチド
BR112021003812A2 (pt) terapias peptídicas para o tratamento de câncer e usos das mesmas